Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization

Arai, Takuma; Kobayashi, Adam; Ohya, Ayumi; Takahashi, Masaaki; Yokoyama, Tetsuji; Shimizu, Akira; Motoyama, Hiroaki; Furusawa, Norihiko; Noguchi, Tsuyoshi; Kitagawa, Noriyuki; Sakai, Hiroshi; Imamura, Hiroshi; Kadoya, Masumi; Miyagawa, Shinichi

doi:10.1007/s10147-013-0634-6

Cited by 24 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The objective response rate using enhancement criteria ranges between 58 and 86%, and 20–41% achieve complete response [538, 541–543]. In addition, the biological response based upon changes in tumor markers after treatment might be used as an ancillary method for assessment of overall response [544, 545]. …”

Section: Decisions On Resectability Of Hccmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

show abstract

Section: Decisions On Resectability Of Hccmentioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For patients treated with sorafenib, an early decrease in serum AFP levels indicates a higher probability of response [ 11 ]. In HCC patients receiving transarterial chemoembolization (TACE), the response of AFP and PIVKA-II is positively associated with the radiological response [ 12 , 13 ]. However, the predictive role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 therapy remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

et al. 2021

View full text Add to dashboard Cite

Background Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy. Methods A total of 235 HCC patients treated with PD-1 blockade were enrolled. Serum AFP and PIVKA-II levels were collected before and after treatments. The patients were divided into groups based on the reduction in AFP and PIVKA-II: AFP reduction ≤50% vs AFP reduction > 50% and PIVKA-II reduction ≤50% vs PIVKA-II reduction > 50%. The primary endpoints included objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Binary logistic regression analyses were used to explore the related factors of ORR. A Cox proportional hazards model was employed to identify the potential prognostic factors of PFS and OS. Results Among all the patients, 34.9% (82/235) achieved a complete or partial response. There was a positive correlation between AFP reduction > 50% or PIVKA-II reduction> 50% and the ORR of PD-1 blockade (P < 0.001 and = 0.003). PFS was significantly improved in patients with AFP reduction > 50% and PIVKA-II reduction > 50% (p < 0.001 and = 0.021). In addition, AFP reduction > 50% and PIVKA-II reduction> 50% were positively correlated with longer OS (p = 0.003 and 0.006). Conclusion Early reductions in AFP and PIVKA-II can be predictors of the efficacy of PD-1 blockade in HCC patients.

show abstract

“…Serum alpha-fetoprotein (AFP) is the most widely used tumour marker in patients with HCC and has been proven to have capability of prefiguring the prognosis [29] and aid in monitoring for tumour recurrence [30]. Recently it has been shown that protein induced by vitamin K absence, antagonist-II (PIVKA-II), effectively increases the detection rate of HCC as a valid complement to AFP and imaging surveillance [31].…”

Section: Laboratory Findingsmentioning

confidence: 99%

CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation

Lucatelli

Burrel

Guiu

et al. 2021

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

This CIRSE Standards of Practice document is aimed at interventional radiologists and provides best practices for performing transarterial chemoembolisation. It has been developed by an expert writing group under the guidance of the CIRSE Standards of Practice Committee. It will encompass all technical details reflecting European practice of different TACE procedures (Lp-TACE, DEM-TACE, DSM-TACE, b-TACE) as well as revising the existing literature on the various clinical indications (HCC, mCRC, ICC, NET). Finally, new frontiers of development will also be discussed.

show abstract

Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization

Abstract: The DCP trend might be useful for assessing treatment outcomes after TACE in patients with recurrent HCC.

Cited by 24 publications

References 41 publications

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation

Contact Info

Product

Resources

About